Q2 FY2026 · ended Jun 30, 2026 · Revenue $5,360, -28.3% YoY · Filed Aug 7, 2026
Cardio Diagnostics Holdings, Inc. (CDIO) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $5,360 and a net loss of $1.5 million. Free cash flow was -$1.3 million. As of Jun 30, 2026 it held $0 in cash and investments and $302,250 in total debt.
Revenue
$5,360
-28.3% vs year-ago quarter
Net income
$-1.50M
+10.8% vs year-ago quarter
Operating cash flow
$-1.34M
+14.6% vs year-ago quarter
Free cash flow
$-1.34M
+15.6% vs year-ago quarter
EPS
$-0.51
+47.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.96M
+67.9% vs year-ago quarter
Net cash
$-302,250
Q2 FY2026
Operating margin
-44690.7%
TTM
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CDIO (Nasdaq), CDIOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870144
- Former names
- Mana Capital Acquisition Corp. (until Oct 26, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5,360 | $2,680 | $3,555 | $2,855 | $7,475 |
| Operating income | -$1.5M | -$1.8M | -$1.5M | -$1.7M | -$1.7M |
| Net income | -$1.5M | -$1.8M | -$1.5M | -$1.7M | -$1.7M |
| Diluted EPS | -$0.51 | -$0.63 | -$0.80 | -$0.98 | -$0.97 |
| Operating cash flow | -$1.3M | -$1.6M | -$1.4M | -$1.4M | -$1.6M |
| Free cash flow | -$1.3M | -$1.6M | -$1.4M | -$1.6M | -$1.6M |
| Total assets | $7.9M | $9.6M | $7.8M | $8.8M | $10.4M |
| Total liabilities | $499,780 | $655,972 | $793,061 | $637,331 | $671,848 |
| Stockholders' equity | $7.4M | $8.9M | $7.0M | $8.2M | $9.7M |
| Cash and investments | $0 | $0 | $0 | $0 | $0 |
| Total debt | $302,250 | $364,383 | $302,250 | $486,597 | $546,433 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 23, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 295 Cardio Diagnostics Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.